Drug
Ryz711
Ryz711: highest development phase Phase 1/2, developed by RayzeBio, Inc.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- RayzeBio, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| RYZ711 NCT07862582 | Phase 1/2 | Prostate Cancer (Adenocarcinoma) |
Latest
No recent events.
Follow Ryz711 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.